STING Agonist to SOS1 Inhibitor, Lupin Lines Up Oncology Pipeline
Partners Sought
From a STING agonist to a SOS1 inhibitor, Lupin listed oncology candidates from the preclinical stage to those in IND-enabling studies during the recently concluded J.P. Morgan conference. Meanwhile, the newly spun-off oncology subsidiary awaits partners.
